ESMO 2023 Prostate Cancer - Results from #20

Viewing 21-40 of 66 articles

ESMO 2023: 177Lu-PSMA-617 in Pre- and Post-Taxane mCRPC Setting: Results from the Phase II IRST-185.03 Clinical Trial

ESMO 2023: Real-World Overall Survival with Enzalutamide and Abiraterone Acetate in Patients with Chemotherapy-Naïve mCRPC

ESMO 2023: The Impact of Baseline PSMA PET/CT versus CT on Outcomes of Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer Patients

ESMO 2023: PSMA-Alpha Targeted Radionuclide Therapy with or without Prior PSMA-Beta Targeted Radionuclide Therapy

ESMO 2023: Invited Discussant: KEYNOTE-641, KEYNOTE-991, MAGNITUDE & ProBio

ESMO 2023: Invited Discussant: More Than Therapy Alone

ESMO 2023: Healthcare Data from the STAMPEDE Docetaxel and Zoledronic Acid Comparisons: Incidence of Fracture Related Hospitalisations in Men with De Novo High Risk and Metastatic Hormone Sensitive Prostate Cancer

ESMO 2023: MAGNITUDE Three-Year Update and Final Analysis: Niraparib with Abiraterone Acetate plus Prednisone as First-Line Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alteration

ESMO 2023: Effects of Enzalutamide on Overall Survival +/- Early Docetaxel in Participants Aged Less than 70 Yrs vs Greater than or Equal to 70 Yrs in ENZAMET (ANZUP 1304)

ESMO 2023: EMBARK: Health-Related Quality of Life in nmHSPC Patients with High-Risk BCR

ESMO 2023: External Validation of a Digital Pathology-Based Multimodal Artificial Intelligence (MMAI)-Derived Model in High-Risk M0/M1 Prostate Cancer Starting ADT in the Docetaxel or Abiraterone Phase 3 STAMPEDE Trials

ESMO 2023: KEYNOTE-641 Phase 3: Pembrolizumab plus Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

ESMO 2023: KEYNOTE-991 Pembrolizumab plus Enzalutamide and Androgen Deprivation Therapy for Patients with Metastatic Hormone-Sensitive Prostate Cancer

ESMO 2023: Health-Related Quality of Life Deterioration-Free Survival by PSA Decline in Darolutamide-Treated Patients with Nonmetastatic Castration-Resistant Prostate Cancer from ARAMIS

ESMO 2023: ProBio, a Randomized, Outcome-Adaptive, Biomarker-Driven Platform Trial: AR Pathway Inhibitors or Taxanes for Patients with Metastatic Castration-Resistant Prostate Cancer: A Direct Comparison

ESMO 2023: Efficacy of Olaparib + Abiraterone vs Placebo + Abiraterone in the Non-BRCA Mutation Subgroup of Patients with mCRPC in the PROpel Trial

ESMO 2023: PSA Outcomes with Darolutamide, ADT and Docetaxel in Patients with High- and Low-Volume Metastatic Hormone-Sensitive Prostate Cancer in ARASENS

ESMO 2023: Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Lymphopenia in Patients with mCRPC Treated with 177Lu-PSMA-617: VISION Post Hoc Analysis

ESMO 2023: Molecular Features of Circulating Tumor Cells Associated with Response to 177LuPSMA + Pembrolizumab for Metastatic Castration Resistant Prostate Cancer

ESMO 2023: Combination Treatment with Radium-223 and Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer in the REASSURE Study

1
2
3
4